BIJOY HANS LTD.

Bijoy Hans Ltd has announced the closure of its trading window for designated persons and their relatives, effective July 1, 2026. This closure is in anticipation of the declaration of the company's unaudited financial results for the first quarter ended June 30, 2026. The trading window will reopen 48 hours after the results are declared. The company also stated that the PAN of designated persons and their relatives will be frozen during this period as per SEBI regulations to prevent insider trading. The exact date of the board meeting to approve these results will be communicated separately.

The company 524723 submitted its Statement of Deviation(s) and/or variation(s) under Regulation 32 of SEBI LODR for the quarter ended March 31, 2026. The company clarified that the statement is not applicable as it had allotted equity shares on a preferential basis for consideration other than cash, specifically through a share swap for acquisition. Since no cash proceeds were raised from this issuance, there were no funds available for utilization, rendering the deviation statement irrelevant for the period.

Arvaya Healthcare Limited's Board of Directors, at its meeting on May 28, 2026, noted the resignation of Mr. Aslesh Ramchandra Parannawar as the Internal Auditor, effective April 20, 2026. Subsequently, based on the Audit Committee's recommendation, the Board approved the appointment of M/s. G K Vora & Co., Chartered Accountants, as the new Internal Auditor for the Financial Year 2026-27. The board meeting also approved the Audited Financial Results for the quarter and financial year ended March 31, 2026, with an unmodified opinion from statutory auditors.

Arvaya Healthcare Limited's Board of Directors, in a meeting on May 28, 2026, approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The statutory auditors, M/s. Khire Khandekar & Kirloskar, provided an unmodified opinion on these results. Additionally, the Board noted the resignation of Mr. Aslesh Ramchandra Parannawar as Internal Auditor and approved the appointment of M/s. G K Vora & Co. as the new Internal Auditor for FY 2026-27.

Arvaya Healthcare Limited's Board of Directors, at its meeting on May 28, 2026, approved the Audited Financial Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026. The statutory auditors, M/s. Khire Khandekar & Kirloskar, provided an unmodified opinion on these results. Additionally, the Board acknowledged the resignation of Mr. Aslesh Ramchandra Parannawar as the Internal Auditor, effective April 20, 2026, and subsequently approved the appointment of M/s. G K Vora & Co. as the new Internal Auditor for the Financial Year 2026-27.

Bijoy Hans Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited financial statements (standalone and consolidated) for the fourth quarter and year ended March 31, 2026. The trading window for dealing in the company's shares is closed from April 1, 2026, to May 30, 2026.

Bijoy Hans Limited has officially changed its name to Arvaya Healthcare Limited, effective May 11, 2026. The Registrar of Companies approved the name change, and a revised Certificate of Incorporation has been issued. The company's Memorandum and Articles of Association have been updated accordingly.

Bijoy Hans Ltd's Board of Directors, through a circular resolution on April 28, 2026, approved the identification of Those Charged with Governance (TCWG) and adopted a related policy. In accordance with the NFRA Circular dated January 7, 2026, the company's Audit Committee has been designated as the primary TCWG for all audit-related communications. The Audit Committee comprises Mr. Rahul Ravindra Mayur (Chairperson), Mr. Brijesh Jugalkishor Biyani, and Mr. Kaushal Uttam Shah. Additionally, Mr. Ranganath Abhiram, Chief Financial Officer, was appointed as the Nodal Officer. The Board also approved and adopted a Policy on Statutory Auditor–TCWG Two-Way Communication Framework, aligning with NFRA requirements.

Bijoy Hans Ltd has received trading approval from BSE Limited for 4,05,21,836 equity shares. These shares, with a face value of ₹10 each, were issued at a premium of ₹2.50 on a preferential basis to both promoters and non-promoters. The trading approval was granted on April 22, 2026, and the securities became effective for listing on the Exchange from Thursday, April 23, 2026. This action is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011, promoters of Bijoy Hans Ltd, including Kaushal Shah, Pankaj Samani, Ravidutt Ashitbhai Parikh, and Shantanu Jagannath Surpure, have declared that no encumbrance was made over the shares of the company during the financial year ended 31st March, 2026. As of March 31, 2026, the number of encumbered or pledged shares by promoters of Bijoy Hans Ltd is nil.